Science Explorer Back to mapMap

Most cited papers from Levine Cancer Institute

What are the most cited papers from Levine Cancer Institute?

The most cited paper from Levine Cancer Institute is "The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging" (Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al., 2017), with 6,689 citations. Next come "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" (5,031) and "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma" (3,102).

Showing 50 of 59 papers. Every paper with more than 311 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians Open access 17 Jan 2017 6,689
2 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S. Vincent Rajkumar et al. · The Lancet Oncology Open access 26 Oct 2014 5,031
3 International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Shaji Kunnathu Kumar et al. · The Lancet Oncology 26 Jul 2016 3,102
4 Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Jeremy S Abramson et al. · The Lancet Sep 2020 2,422
5 AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Pasi Antero Janne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine Open access 29 Apr 2015 2,135
6 Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja et al. · The Lancet 24 Jun 2021 1,751
7 Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases Paul David Brown, Kurt A. Jaeckle, Karla V. Ballman et al. · JAMA Open access 26 Jul 2016 1,689
8 Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Meletios Athanasios Dimopoulos et al. · New England Journal of Medicine Open access 5 Oct 2016 1,454
9 Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Yohann Loriot et al. · New England Journal of Medicine Open access 24 Jul 2019 1,396
10 Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Scott Joseph Antonia et al. · The Lancet Oncology Open access 5 Jun 2016 1,263
11 Teclistamab in Relapsed or Refractory Multiple Myeloma Philippe Moreau et al. · New England Journal of Medicine Open access 5 Jun 2022 1,239
12 CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma Ranjana H. Advani et al. · New England Journal of Medicine Open access 31 Oct 2018 1,149
13 Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Thierry T.F. Facon et al. · New England Journal of Medicine Open access 29 May 2019 1,022
14 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Pieter Sonneveld et al. · Blood Open access 22 Mar 2016 945
15 Primary Prevention of Ischemic Stroke Larry B. Goldstein, Robert J. Adams, Kyra J. Becker et al. · Stroke 2001 908
16 Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Sagar Lonial et al. · The Lancet 6 Jan 2016 857
17 Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline Michael A. Vogelbaum et al. · Journal of Clinical Oncology Open access 21 Dec 2021 844
18 Results of coronary artery surgery in patients with poor left ventricular function (CASS). Edwin L. Alderman, Lloyd D. Fisher, Paul E. Litwin et al. · Circulation Open access Oct 1983 815
19 Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Sagar Lonial et al. · The Lancet Oncology 16 Dec 2019 814
20 Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Sylvia Adams et al. · Annals of Oncology Open access 22 Nov 2018 810
21 Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert John Motzer et al. · The Lancet Oncology Open access 16 Aug 2019 797
22 Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I Steven C. Campbell, Peter E. Clark, Sam S. Chang et al. · The Journal of Urology 11 Jun 2021 782
23 Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Alok A. Khorana et al. · New England Journal of Medicine Open access 20 Feb 2019 725
24 Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib Geoffrey R. Oxnard, Yuebi Hu, Kathryn Finch Mileham et al. · JAMA Oncology Open access 2 Aug 2018 705
25 Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Peter Michael Voorhees et al. · Blood Open access 23 Apr 2020 701
26 Congenital coronary arteriovenous fistula. Report of 13 patients, review of the literature and delineation of management. R R Liberthson, Kiran B. Sagar, J P Berkoben et al. · Circulation Open access May 1979 680
27 Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial Catherine A. Shu, Justin F. Gainor, Mark Magdi Awad et al. · The Lancet Oncology 7 May 2020 649
28 Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology Open access 22 Nov 2018 644
29 International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease David C. Fajgenbaum et al. · Blood Open access 13 Jan 2017 641
30 Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer Naiyer A. Rizvi et al. · JAMA Oncology Open access 9 Apr 2020 640
31 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Ujjawal H. Gandhi et al. · Leukemia Open access 11 Mar 2019 625
32 Intermittent versus Continuous Androgen Deprivation in Prostate Cancer Maha Hussain et al. · New England Journal of Medicine Open access 3 Apr 2013 584
33 The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group Nelson Leung et al. · Nature Reviews Nephrology ReviewOpen access 3 Dec 2018 553
34 Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group Michèle Cavo et al. · The Lancet Oncology 30 Mar 2017 545
35 Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms Eli L. Diamond et al. · Cancer Discovery Open access 13 Nov 2015 542
36 Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter Michael K. Lim et al. · Neuro-Oncology Open access 28 Apr 2022 536
37 Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial Antonio M. P. Omuro et al. · Neuro-Oncology Open access 14 Apr 2022 522
38 International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders Jens Hillengaß et al. · The Lancet Oncology Open access 29 May 2019 519
39 Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma Paul Gerard Guy Richardson et al. · New England Journal of Medicine Open access 5 Jun 2022 494
40 Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim et al. · The Lancet Oncology Open access 8 Aug 2017 480
41 Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline Gregory M.M. Videtic, Jessica Scott Donington, Meredith Elana Giuliani et al. · Practical Radiation Oncology Open access 5 Jun 2017 477
42 Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer Shaveta Vinayak, Sara M. Tolaney, Lee Steven Schwartzberg et al. · JAMA Oncology Open access 13 Jun 2019 457
43 A Review of the Evidence for the Use of Telemedicine Within Stroke Systems of Care Lee H. Schwamm, Robert G. Holloway, Pierre Amarenco et al. · Stroke 8 May 2009 453
44 Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial Robert Wendel Naumann, Antoine Hollebecque, Tim Meyer et al. · Journal of Clinical Oncology Open access 5 Sep 2019 443
45 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices Julia H. Indik et al. · Heart Rhythm 11 May 2017 438
46 International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease Frits van Rhee et al. · Blood Open access 4 Sep 2018 427
47 Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations Sergio A. Giralt, Luciano J. Costa, Jeffrey R. Schriber et al. · Transplantation and Cellular Therapy Open access 17 Oct 2013 411
48 Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood Open access 24 May 2016 407
49 Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial Thierry T.F. Facon et al. · The Lancet Oncology Open access 14 Oct 2021 375
50 Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology Open access 2 Oct 2020 367

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.